PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer
- PeptiCRAD is a platform combining oncolytic adenovirus and peptide vaccination in cancer
- Peptide antigens are non-covalently/electrostatically attached to the virus surface without compromising OV activity and generate potent cytotoxic CD8+ T cell responses to tumors
- PeptiCRAd offers an ideal platform to test novel neoantigens preclinically and in the clinic